A systematic review of the genetic mechanisms of dolutegravir resistance
Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
Two'sa company, three'sa crowd: A review of initiating or switching to a two-drug antiretroviral regimen in treatment-naïve and treatment-experienced patients living …
M Badowski, SE Pérez, D Silva, A Lee - Infectious Diseases and Therapy, 2020 - Springer
Introduction As HIV has become a manageable chronic condition, a renewed and increased
interest in challenging traditional three-drug HIV therapies and moving toward two-drug …
interest in challenging traditional three-drug HIV therapies and moving toward two-drug …
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data
AF Capetti, MV Cossu, G Orofino, G Sterrantino… - BMC Infectious …, 2017 - Springer
Background Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of
drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy …
drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy …
Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV Practice …
D Chastain, M Badowski, E Huesgen… - Journal of the …, 2019 - journals.sagepub.com
Simplifying or switching antiretroviral therapy (ART) in treatment-experienced people living
with HIV (PLWH) may improve adherence, tolerability, toxicities, and/or drug–drug …
with HIV (PLWH) may improve adherence, tolerability, toxicities, and/or drug–drug …
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects
AF Capetti, GV De Socio, MV Cossu… - HIV Clinical …, 2018 - Taylor & Francis
Background: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-
friendly salvage regimen with the highest genetic barrier to HIV-1 resistance. Objective: Aim …
friendly salvage regimen with the highest genetic barrier to HIV-1 resistance. Objective: Aim …
Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection
AF Capetti, MV Cossu, L Paladini… - Expert Opinion on …, 2018 - Taylor & Francis
Introduction: The HIV-infected population is aging and comorbidities and
polypharmacological regimens are increasing. To reduce toxicity and drug burden …
polypharmacological regimens are increasing. To reduce toxicity and drug burden …
[PDF][PDF] Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with …
Background: Dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG/DRV/c)
is reasonable alternative option for patients with existing resistance and/or intolerance to …
is reasonable alternative option for patients with existing resistance and/or intolerance to …
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
ER Elliot, M Cerrone, E Challenger… - Journal of …, 2019 - academic.oup.com
Background Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing
and/or salvage strategy for the treatment of HIV-1 infection. Methods This Phase I, open …
and/or salvage strategy for the treatment of HIV-1 infection. Methods This Phase I, open …
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy
A Castagna, S Rusconi, R Gulminetti, S Bonora… - AIDS, 2019 - journals.lww.com
We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG)
and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than …
and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than …
Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective
People with HIV (PWH) increasingly benefit from effective, convenient antiretroviral therapy
(ART) thanks to fixed-dose combinations (FDCs) of new medications with a high barrier to …
(ART) thanks to fixed-dose combinations (FDCs) of new medications with a high barrier to …